On Monday 12th October, the BioIMP initiative was inaugurated in Besançon. Co-financed by the European Regional Development Fund (ERDF) with €17.8 million, the BioIMP (Bioprocess Improvement) project aims to revolutionize the production of biomedicines.
BioIMP: EU-funded project to transform biomedicine production in France
- 18 October 2024
Running from 2024 to 2027, BioIMP unites academic and industrial players in biotechnology and microtechnologies, to optimize the manufacturing of innovative biopharmaceuticals. This project is linked to both the EU's regional development goals and France's ambition to produce 20 domestically made biomedicines by 2030, an important step toward enhancing sovereignty in this high-impact sector.
The European Union's financial support highlights its commitment to strengthening Europe's health technology capabilities and ensuring that advanced therapies can be developed and manufactured within its borders. The MiMédI project, a previous EU-supported initiative, laid the groundwork for BioIMP by bringing together local actors to improve bioproduction processes. Now, BioIMP takes this further, focusing on four main objectives: optimizing biological raw materials, testing new production processes under real conditions, enhancing quality control, and designing cutting-edge biomedicines aligned with clinical needs.
This initiative demonstrates Europe's determination to secure the future of biopharma innovation, reducing reliance on global supply chains, and ensuring access to life-saving treatments for all European citizens. By investing in BioIMP, the EU and France are shaping the next generation of healthcare.